2. Gene
  3. RALY - RALY heterogeneous nuclear ribonucleoprotein Gene

RALY - RALY heterogeneous nuclear ribonucleoprotein Gene

  • 基因
  • 蛋白
  • 疾病
  • 相关产品
  • 直系同源

中文名称：RALY 异质核核糖核蛋白

种属: Homo sapiens

同用名: P542; HNRPCL2

基因 ID: 22913 | 基因类型: protein coding

关于 RALY

Cytogenetic location: 20q11.22 Genomic coordinates (GRCh38): 20:33,993,911-34,084,884 (from NCBI)

This gene has 10 transcripts (splice variants), 203 orthologues and 6 paralogues. Ubiquitous expression in bone marrow (RPKM 18.7), testis (RPKM 18.3) and 25 other tissues.

功能概要

该基因编码异质核核糖核蛋白 (hnRNP) 基因家族的成员。这种蛋白质可能在 pre-mRNA 剪接和胚胎发育中发挥作用。交替剪接导致多个转录本变体。[RefSeq 提供，2011 年 9 月]

This gene encodes a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) gene family. This protein may play a role in pre-mRNA splicing and in embryonic development. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Sep 2011]

RALY 基因产物(2)

mRNA Protein Name
NM_007367.4 NP_031393.2 RNA-binding protein Raly isoform 2
NM_016732.3 NP_057951.1 RNA-binding protein Raly isoform 1

RALY 蛋白结构

RRM_1

RRM_1: RNA recognition motif. (a.k.a. RRM, RBD, or RNP domain) (23 - 85)

  • 0
  • 100
  • 200
  • 306 a.a.
蛋白主名 其他名称

RNA-binding protein Raly

RNA binding protein, autoantigenic (hnRNP-associated with lethal yellow homolog)

关联疾病

疾病名称 别名
Skin Carcinoma In Situ

Carcinoma In Situ Of Skin

Cutaneous Carcinoma In Situ
Bardet-Biedl Syndrome 1

BBS1

Bardet-Biedl Syndrome 1, Modifier Of

Bardet-Biedl Syndrome

BBS

Bardet-Biedl Syndrome, Type 1

Laurence-Moon-Bardet-Biedl Syndrome
疾病名称 别名
Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

相关产品

Approval
生物活性分子 (11)
目录号 产品名 作用方式
纯度 是否罕见病
HY-15771 Tirabrutinib 99.65% 是
HY-15771A Tirabrutinib hydrochloride 99.43% 是
HY-10405 Pamapimod Inhibitor 99.92% 否
HY-P3502 Zilucoplan Inhibitor 95.33% 否
HY-B0524 Betahistine Modulator 98.04% 否
HY-106019 Liarozole Inhibitor 98.83% 是
HY-110159 (E/Z)-Teriflunomide Inhibitor 99.86% 是
HY-D0237 Betahistine mesylate Modulator 99.90% 否
HY-B0160 Lafutidine Antagonist 99.95% 否
HY-B0524A Betahistine dihydrochloride Modulator 99.74% 否
HY-18300A Filgotinib maleate Inhibitor / 否
抗体抑制剂 (1)
目录号 产品名 作用方式
纯度 是否罕见病
HY-P9924 Ixekizumab Inhibitor 98.90% 否
Clinical Phase
生物活性分子 (7)
目录号 产品名 作用方式
纯度 Phase
HY-10291 Tarenflurbil Inhibitor 99.96% Phase 3
HY-106019C Liarozole dihydrochloride Inhibitor ≥99.0% Phase 3
HY-14531 Talarozole Inhibitor 99.61% Phase 2
HY-18099A S1RA hydrochloride Antagonist 99.85% Phase 2
HY-18099 S1RA Antagonist 99.43% Phase 2
HY-147264 Edecesertib Inhibitor 99.86% Phase 2
HY-101671 S-methyl-KE-298 ≥98.0% Phase 2
抗体抑制剂 (8)
目录号 产品名 作用方式
纯度 Phase
HY-P99210 Olokizumab Inhibitor 95.85% Phase 3
HY-P99252 Itolizumab 95.00% Phase 3
HY-P99661 Inbakicept Activator 98.95% Phase 2
HY-P99259 Cabiralizumab Inhibitor 99.59% Phase 2
HY-P99385 Vobarilizumab Inhibitor 97.36% Phase 2
HY-P99870 Eblasakimab ≥99.0% Phase 2
HY-P99642 Gimsilumab Inhibitor / Phase 2
HY-P99940 Remtolumab Inhibitor 99.24% Phase 2
Pre-clinical Phase
生物活性分子 (92)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-N0142 Phloretin Inhibitor 99.67% 否
HY-125099A AFM-30a hydrochloride Inhibitor 99.96% 否
HY-147141 HS-276 Inhibitor 98.59% 否
HY-P0204A Endothelin-3, human, mouse, rabbit, rat TFA 99.51% 否
HY-100739 RA190 Inhibitor 99.09% 否
HY-103169 SCH442416 Antagonist 99.68% 否
HY-15898 Y-320 99.74% 否
HY-111532 (3R,4R)-A2-32-01 Inhibitor 99.43% 否
HY-108522 PA452 Antagonist ≥99.0% 否
HY-110275 RA839 98.90% 否
HY-136528 RA-9 98.67% 否
HY-N1976 (+)-(3R,8S)-Falcarindiol Inhibitor 99.88% 否
HY-N2435 [8]-Shogaol 99.93% 否
HY-147972 NF-κB/MAPK-IN-1 Inhibitor 98.42% 否
HY-50081 CCR2-RA-[R] Antagonist 99.71% 否
HY-118530 Bucillamine Inhibitor 98.87% 是
HY-136563 RA375 99.31% 否
HY-21545 5'-O-DMT-Bz-rA ≥98.0% 否
HY-103175 PSB36 Antagonist ≥99.0% 否
HY-125415 PF-4693627 Inhibitor 99.63% 否
HY-139314 A2B receptor antagonist 2 Antagonist 99.88% 否
HY-103174 MRS1334 Antagonist ≥99.0% 否
HY-125099 AFM-30a Inhibitor ≥96.0% 否
HY-N1440 Koumine Activator 99.97% 否
HY-N2506 Ginsenoside Ra1 99.77% 否
HY-N4260 Ginsenoside Ra2 95.95% 否
HY-21703 3'-TBDMS-Bz-rA Phosphoramidite ≥98.0% 否
HY-147660 IMMH001 Agonist / 否
HY-104017 DMT-2'-O-MOE-rA(Bz) phosphoramidite / 否
HY-126114 Lupeol acetate Inhibitor ≥98.0% 否
HY-N10790 RA-V 99.58% 否
HY-N4259 Ginsenoside Ra3 98.24% 否
HY-W018179 5'-DMT-3'-TBDMS-Bz-rA 99.19% 否
HY-W006102 Bz-rA Phosphoramidite 97.58% 否
HY-100707 IC 86621 Inhibitor / 否
HY-103177 PSB-10 hydrochloride Inhibitor / 否
HY-107495 Betahistine EP Impurity C Modulator / 否
HY-107644 AQ-RA 741 Antagonist / 否
HY-107730 NPY5RA-972 Antagonist 98.86% 否
HY-118689 RA-2 Modulator / 否
HY-127150 Clofezone / 否
HY-135376 Atorvastatin methyl ester / 否
HY-135378 Atorvastatin ethyl ester / 否
HY-135453 (-)-Pinocembrin Inhibitor / 否
HY-139654 α/β-Hydrolase-IN-1 Inhibitor / 否
HY-143290 Antibacterial agent 118 Inhibitor / 否
HY-146104 Antimycobacterial agent-1 Inhibitor / 否
HY-149064 Antituberculosis agent-9 Inhibitor / 否
HY-149581 DprE1-IN-9 Inhibitor / 否
HY-150658S DMT-2′O-TBDMS-rA(ac)-1-15N phosphoramidite / 否
HY-151472 hCAIX/XII-IN-6 Inhibitor / 否
HY-152035 Mycobacterial Zmp1-IN-1 Inhibitor / 否
HY-153333 A1/A3 AR antagonist 3 Antagonist / 否
HY-153489 ISIS 329993 Inhibitor / 否
HY-153489A ISIS 329993 sodium Inhibitor / 否
HY-154961 Mcl-1 inhibitor 14 / 否
HY-154962 Mcl-1 inhibitor 15 Inhibitor / 否
HY-155031 MCI Inhibitor / 否
HY-B0160S Lafutidine-d10 Antagonist / 否
HY-B0524AS Betahistine-d3 dihydrochloride Modulator ≥99.0% 否
HY-B0524AS1 Betahistine-13C,d3 dihydrochloride Modulator / 否
HY-D2279 NFL-NH2 / 否
HY-N0142R Phloretin (Standard) Inhibitor / 否
HY-N10793 RA-XI / 否
HY-N11646 Ganorbiformin B Inhibitor / 否
HY-N11650 (22S,24E)-3β,22-Diacetoxylanosta-7,9(11),24-trien-26-oic acid Inhibitor / 否
HY-N11957 Angeloylbinankadsurin A / 否
HY-N12015 Ginsenoside Ra6 / 否
HY-N12648 Anemarsaponin E1 / 否
HY-N3612 Communic acid Inhibitor / 否
HY-P3491 Pegloxenatide Agonist / 否
HY-P3502A Zilucoplan TFA Inhibitor / 否
HY-RS03232 CSF2RA Human Pre-designed siRNA Set A / 否
HY-RS06673 IL10RA Human Pre-designed siRNA Set A / 否
HY-RS06676 IL11RA Human Pre-designed siRNA Set A / 否
HY-RS06688 IL13RA1 Human Pre-designed siRNA Set A / 否
HY-RS06689 IL13RA2 Human Pre-designed siRNA Set A / 否
HY-RS06693 IL15RA Human Pre-designed siRNA Set A / 否
HY-RS06702 IL17RA Human Pre-designed siRNA Set A / 否
HY-RS06732 IL20RA Human Pre-designed siRNA Set A / 否
HY-RS06737 IL22RA1 Human Pre-designed siRNA Set A / 否
HY-RS06738 IL22RA2 Human Pre-designed siRNA Set A / 否
HY-RS06747 IL27RA Human Pre-designed siRNA Set A / 否
HY-RS06748 IL2RA Human Pre-designed siRNA Set A / 否
HY-RS06755 IL31RA Human Pre-designed siRNA Set A / 否
HY-RS06764 IL3RA Human Pre-designed siRNA Set A / 否
HY-RS06773 IL5RA Human Pre-designed siRNA Set A / 否
HY-RS11635 RALY Human Pre-designed siRNA Set A / 否
HY-105934A Ketotrexate sodium / 否
HY-N2876 Anisofolin A Inhibitor / 否
HY-103046 UbcH5c-IN-1 Inhibitor / 否
HY-U00420 Opioid receptor modulator 1 Modulator / 否
抗体抑制剂 (6)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-P99287 Elsilimomab Inhibitor 95.00% 否
HY-P9923A Benralizumab (anti-IL5RA ) 99.60% 否
HY-P990016 Temtokibart Inhibitor 99.23% 否
HY-P99487 Briobacept 97.66% 否
HY-P990086 Vopikitug Inhibitor / 否
HY-P99782 Opinercept Inhibitor / 否

直系同源

种属 基因名 来源 基因 ID
Mus musculus RALY MGD MGI:97850
Bos taurus RALY VGNC VGNC:33706
Rattus norvegicus RALY RGD RGD:1307228
Canis familiaris RALY VGNC VGNC:45337
Felis catus RALY VGNC VGNC:81167
Macaca mulatta RALY VGNC VGNC:76486
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z